The European Commission recently awarded Cergentis a €1.2 million grant to support the development of its TLA technology for use in FFPE samples.
The Fix-C method is a modified version of Hi-C and makes use of the fact that the structural information relevant in cancer is preserved in FFPE samples.
UK researchers have dug into the archive to find more cancer samples for sequencing, Nature News reports.
The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.
Two researchers devised a protocol to sequence DNA from ancient samples and tested it on 100-year-old museum specimens.
The combination of the new test with Biocartis' existing KRAS assay offers customers a complete solution for testing metastatic colorectal cancers as reccomended by professional guidelines.
The company plans to raise $25 million in a Series B financing round. It is also working on a two-color chemistry and aims to develop an instrument for clinical applications.
The diagnostic, a real-time PCR kit for breast cancer stratification, is being reviewed under a special process for the approval of innovative products.
Earlier this month at AGBT, company researchers presented the new developments, which Thermo Fisher plans to roll out later this year.
They plan to combine Silicon’s DEPArray digital-sorting technology with Macrogen’s NGS systems to develop genomic tests for different cancers.
Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.
According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.
In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.
CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.